Influenza virus resistance to antiviral agents: A plea for rational use

Clinical Infectious Diseases

Volumn 48, Issue 9, 2009, Pages 1254-1256

  Poland, Gregory A ^a   Jacobson, Robert M ^a   Ovsyannikova, Inna G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; AMANTADINE; ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

ANTIBIOTIC SENSITIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL TRIAL; DIAGNOSTIC TEST; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; LOWER RESPIRATORY TRACT INFECTION; MEDICAL SOCIETY; MONOTHERAPY; MULTIDRUG RESISTANCE; POINT OF CARE TESTING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT INDICATION; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS RESISTANCE; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TRANSMISSION; ANIMAL; ARTICLE; DRUG COMBINATION; DRUG EFFECT; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1;

ADAMANTANE; ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; OSELTAMIVIR;

EID: 65549113423     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598989     Document Type: Short Survey

References (27)

1. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366: 1175-81.
2. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355:827-35.
3. Hay A. Amantadine and rimantadine-mechanisms. In: Richman DD, ed. Antiviral drug resistance. Chichester, United Kingdom: John Wiley & Sons, 1996:43-58.
4. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992; 176:119-30.
5. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295:891-4.
6. Centers for Disease Control and Prevention. Update: influenza activity-United States, September 28-November 29, 2008. MMWR Morb Mortal Wkly Rep 2008;57:1329-32.
7. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007; 297:1435-42.
8. Hurt AC, Iannello P, Jachno K, et al. Neu-raminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob Agents Chemo- ther 2006; 50:1872-4.
9. Centers for Disease Control and Prevention. Flu activity & surveillance. Available at: http://www.cdc.gov/flu/weekly/fluactivity .htm. Accessed 20 February 2009.
10. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir- resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009; 15:155-62.
11. Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008; 13:8026.
12. Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after os- eltamivir treatment of acute influenza A and B in children. Clin Infect Dis 2009; 48:389-96.
13. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008;52: 3284-92.
14. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007; 12:603-16.
15. de Jong MD, Tran TT, Truong HK, et al. Os- eltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-72.
16. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127-33.
17. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004;364:759-65.
18. de Jong MD, Tran TT, Truong HK, et al. Os-eltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-72.
19. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009; 48(Suppl 1):S3-13.
20. Monto AS. Implications ofantiviral resistance of influenza viruses. Clin Infect Dis 2009;48: 397-9.
21. Escuret V, Frobert E, Bouscambert-Duchamp M, et al. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J Clin Virol 2008; 41:25-8.
22. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193:760-4.
23. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000; 343: 1282-9.
24. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of os- eltamivir treatment with or without postex- posure prophylaxis. J Infect Dis 2004; 189: 440-9.
25. Ison MG, Gnann JW Jr, Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003;8:183-90.
26. Ilyushina NA, Bovin NV, Webster RG, Go-vorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006;70:121-31.
27. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet 2006;367:303-13.